In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Ocugen (OCGN – Research Report), with a price target of $3.00. The company’s shares closed today at $0.70.
According to TipRanks, Ear is a 4-star analyst with an average return of 13.4% and a 32.14% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Alkermes.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocugen with a $4.13 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Ocugen’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $21.94 million. In comparison, last year the company had a GAAP net loss of $14.53 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.
Read More on OCGN:
- Ocugen Provides Business Update with First Quarter 2023 Financial Results
- OCGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
- Ocugen announces FDA granted ODD for OCU410ST
- Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
